The world's first naturally occurring peptide to restore metabolic health (RMH™).

.It remodels body composition, upports the reduction of visceral fat and helps improve metabolic function, regardless of weight and without adverse side effects – a favorable safety profile in all studies.

PEP19 is a naturally occurring bioactive peptide positioned to restore metabolic health. For the 41.5% of adults globally struggling with central obesity, weight management and nearly half of the adult population facing early metabolic risks, this first-of-its-kind metabolic peptide is set to change the landscape.

This capsule offers a safe, side-effect-free, alternative metabolic support approach for individuals battling weight managment and obesity, type- 2 diabetes, and insulin resistance. It is especially promising for populations who require alternative options for metabolic control, such as those intolerant to current GLP-1 treatments, postmenopausal women, and those managing chronic hypertension and even sleep disorders. By addressing key pathways related to the root causes of cardiometabolic health impact, PEP19 remodels high-risk body fat with a favorable safety profile in studies, without causing lean muscle loss, brain effects, or gastrointestinal distress.

PEP19 Explained

Taken as a simple 10 mg daily oral capsule, PEP19 works from within to support metabolic function. Unlike treatments that rely solely on appetite suppression, PEP19 employs a unified mechanism: it promotes a “browning-like” effect in white fat tissue while simultaneously enhancing the body’s insulin efficiency. This active remodeling of fat tissue safely restores healthy metabolism without requiring drastic behavioral changes or causing adverse symptoms.

The Novel Science Behind

At the cellular level, PEP19 fundamentally addresses metabolic signaling by modulating the peripheral CB1 cannabinoid receptor (CB1R). This highly controlled approach triggers UCP1 activation and thermogenesis, effectively supports the conversion of stored white fat into heat. The result is a precise redistribution of the body’s fat – specifically targeting and reducing dangerous visceral fat around the organs – while significantly improving insulin resistance and cardiovascular markers, all completely independent of weight loss.

Proven Human Efficacy and FDA Approved Safety

The efficacy of PEP19 is supported by independent clinical validation, a Self-Affirmed GRAS (Generally Recognized as Safe), and a growing pipeline of global patents extending through 2033.

PEP19, also known as WATACAP, has undergone a rigorous regulatory process to achieve Self-Affirmed Generally Recognized As Safe (GRAS) status. The process was led by Corey Hilmas, MD, PhD, Chief Regulatory Officer of KGK Science Inc. >>read 

Human Clinical Trials Outcomes:

• 6% reduction in HbA1c metabolic markers and improved insulin sensitivity
• 17% reduction in visceral fat
• 8% reduction in android-to-gynoid fat ratio (DEXA)
• 14% reduction in abdominal skinfold thickness

Proven Safety Profile

Multiple human clinical trials, spanning 60 to 90 days, have consistently reported a favorable safety profile showing no adverse effects. Findings include the preservation of lean muscle mass and an absence of gastrointestinal distress, further establishing PEP19 as a safe option for consumption.

• Neurological Safety – designed to act peripherally (does not cross the blood-brain barrier)
• No behavioral changes required
• Efficacy is not dependent on weight
• No lean mass loss
• No provocation of anxious or depressive behaviors.
• Non toxic – no safety concerns observed in studies
• Non allergenic – no safety concerns observed in studies